Filing Analysis
Adagio Medical Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected two directors and ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 16, 2026.
- Quorum achieved with 16,069,984 shares represented (72.35% of 22,210,459 outstanding shares).
- Orly Mishan and Sean Salmon were elected as directors until the 2029 annual meeting.
- WithumSmith+Brown, PC was ratified as the independent auditor for the fiscal year ending December 31, 2026, with 16,055,195 votes in favor.
Adagio Medical Holdings received a notice from Nasdaq on June 12, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock bid price has been below $1.00 for 30 consecutive business days.
🚩 Red Flags
- Failure to maintain minimum bid price is a primary indicator of negative market sentiment and potential liquidity issues.
- Explicit mention of a potential reverse stock split as a remedy to avoid delisting.
📋 Key Facts
- Notice received from Nasdaq on June 12, 2026.
- Violation is based on the Minimum Bid Price Requirement (bid price < $1.00 for 30 consecutive business days).
- The company has until December 9, 2026, to regain compliance.
- Compliance can be achieved if the bid price closes at or above $1.00 for ten consecutive trading days.
- The company mentions the possibility of a reverse stock split to regain compliance if a second 180-day extension is needed.
Adagio Medical Holdings, Inc. announced the submission of a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System. This system is designed for the treatment of ventricular tachycardia.
📋 Key Facts
- On May 21, 2026, Adagio Medical Holdings, Inc. submitted a Premarket Approval (PMA) application to the FDA.
- The application is for the vCLAS® Ventricular Ablation System.
- The system is indicated for the treatment of ventricular tachycardia.
- The announcement was disclosed under Item 8.01 (Other Events) and accompanied by a press release (Exhibit 99.1).
Adagio Medical Holdings, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a general business update via a press release.
📋 Key Facts
- The filing was made on May 12, 2026, covering the fiscal quarter ended March 31, 2026.
- The company utilized Item 2.02 (Results of Operations and Financial Condition) to disclose the earnings release.
- A press release was furnished as Exhibit 99.1.
- The company is classified as an emerging growth company.
Adagio Medical Holdings announced positive pivotal clinical trial results for its vCLAS® Ventricular Ablation System on April 26, 2026. The disclosure was made via a press release filed under Item 8.01 of Form 8-K.
📋 Key Facts
- Announcement of positive pivotal results for vCLAS® Ventricular Ablation System on April 26, 2026
- The company is an emerging growth company as defined by the SEC
- The filing includes Exhibit 99.1, the full press release text
- The report was signed by Deborah Kaster, CFO and Chief Business Officer
Adagio Medical Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 16, 2026. The filing establishes the record date and the deadlines for stockholders to submit director nominations or other proposals.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is set for June 16, 2026.
- The record date for stockholders entitled to vote is April 24, 2026.
- Stockholder proposals for inclusion in proxy materials (Rule 14a-8) must be received by April 30, 2026.
- Director nominations and other proposals under the Company's Bylaws must be submitted by April 30, 2026.
- Notice for director nominees under the SEC's universal proxy rules (Rule 14a-19) is due by April 30, 2026.
Adagio Medical Holdings announced it has received Investigational Device Exemption (IDE) approval from the FDA for its next-generation vCLAS™ Ventricular Ablation System. This regulatory milestone allows the company to commence clinical investigations of the device in the United States.
📋 Key Facts
- FDA IDE approval received on April 8, 2026
- The approval pertains to the vCLAS™ Ventricular Ablation System
- The announcement was made via a press release titled 'Adagio Medical Receives IDE Approval from the FDA to Investigate the Next-Generation vCLAS™ Ventricular Ablation System'
- The filing was made under Item 8.01 (Other Events)
Adagio Medical Holdings, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, via a press release on March 26, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was furnished as Exhibit 99.1.
- The report date is March 26, 2026.